21 . October , 2018 - Sunday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Mitoxantrone

Big Image Pronouncation: (mye-toe-ZAN-trone)
Class: Anthracenedione, Immunomodulator

Trade Names:
- Injection 2 mg (as base)/mL

Mechanism of Action


Has a cytocidal effect on proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity.



Distribution to tissues is extensive and is 78% protein bound over a 26 to 455 ng/mL concentration range. Vd exceeds 1,000 L/m 2 .


Elimination is slow via renal and hepatobiliary systems. Only 11% is recovered in urine within 5 days (65% unchanged, 35% as metabolite); hepatobiliary is more significant, with 25% recovered in feces within 5 days. The elimination t ½ is 23 to 215 hr (median, approximately 75 hr).

Special Populations

Renal Function Impairment

Effects have not been determined.

Hepatic Function Impairment

Patients with multiple sclerosis (MS) who have hepatic function impairment should not ordinarily be treated with mitoxantrone. Dosage adjustment may be required for other patients with hepatic function impairment.

Indications and Usage

Adult acute nonlymphocytic leukemia (ANLL) as adjunctive therapy; advanced hormone-refractory prostate cancer (in combination with corticosteroids); secondary (chronic) progressive, progressive-relapsing, or worsening relapsing-remitting MS.

Unlabeled Uses

Treatment of breast cancer, non-Hodgkin lymphoma, autologous bone marrow transplantation.


Standard considerations.

Dosage and Administration

Combination Initial Therapy for ANLL

IV For induction, give 12 mg/m 2 /day on days 1 to 3, and give cytarabine 100 mg/m 2 for 7 days as a continuous 24-hr infusion on days 1 to 7. A second induction course may be given. Give mitoxantrone for 2 days and cytarabine for 5 days using the same daily dosage levels.

Prostate Cancer

IV 12 to 14 mg/m 2 given as a short IV infusion q 21 days.


IV 12 mg/m 2 given as a short (approximately 5 to 15 min) IV infusion q 3 mo. Do not administer to MS patients who have received a cumulative lifetime dose of 140 mg/m 2 or more, or those with left ventricular ejection fraction (LVEF) of less than 50% or a clinically significant reduction in LVEF.

General Advice

  • Concentrate must be diluted following manufacturer's recommendations before administration. Administer immediately after dilution.
  • Do not administer if particulate matter or discoloration noted.
  • Administer prescribed dose slowly (over period of not less than 3 min) into free-flowing IV infusion.
  • Do not mix with other medications.
  • Discard any unused infusion solution.
  • Follow procedures for proper handling and disposal of anticancer drugs. Wear goggles, gloves, and protective gowns during preparation and administration.


Store unopened vials at controlled room temperature (59° to 77°F). Do not freeze. After penetration of multidose vial stopper, the remaining undiluted concentrate can be stored for up to 7 days at room temperature (59° to 77°F) or refrigerated for up to 14 days at 36° to 46°F. Do not freeze.

Drug Interactions

Quinolone antibiotics

Mitoxantrone may decrease oral absorption of quinolone antibiotics.

Laboratory Test Interactions

None well documented.

Adverse Reactions


Arrhythmia (18%); abnormal ECG (11%).


Headache (6%).


Alopecia (61%).


Sinusitis (6%).


Nausea (76%); diarrhea (25%); stomatitis (19%); constipation (14%).


Menstrual disorder (61%); amenorrhea (43%); UTI (32%); abnormal urine (11%).


Leukopenia (19%); anemia, granulocytopenia (6%).


Increased gamma-glutamyltransferase (15%); increased AST (9%); increased ALT (6%).


Upper respiratory tract infection (53%).


Back pain (8%).




Administer mitoxantrone under the supervision of a health care provider experienced in the use of cytotoxic chemotherapy. Administer into a free-flowing IV infusion.


Cardiotoxicity, including fatal CHF, may occur during, and for years after stopping, mitoxantrone therapy. The risk increases with cumulative dose. Cardiotoxicity may occur whether or not cardiac risk factors are present. However, presence or history of CV disease, prior or concomitant radiotherapy to the mediastinal/pericardial area, previous therapy with anthracyclines or anthracenediones, or concurrent use of other cardiotoxic agents may increase the risk of cardiac toxicity.

Extravasation risk

Local irritation or phlebitis may occur. Refer to institution-specific protocol.


Not for intrathecal use.


Secondary acute myelogenous leukemia has been reported in cancer patients treated with agents related to mitoxantrone.


Except for the treatment of ANLL, do not administer to patients with baseline neutrophil counts less than 1,500 cells/mm 3 .


Perform baseline evaluation of LVEF by echocardiogram or multigated radionuclide angiography (MUGA). Do not treat MS patients with mitoxantrone when their baseline LVEF is less than 50%. Reevaluate LVEF by echocardiogram or MUGA prior to administration of each dose to patients with MS. Obtain a CBC, including platelets, and perform LFTs prior to each course of therapy.


Category D .


Excreted in breast milk. Discontinue breast-feeding upon starting treatment.


Safety and efficacy not established.

Hepatic Function

There is no laboratory measurement that allows for dose adjustment recommendations. Patients with MS who have hepatic function impairment should ordinarily not be treated with mitoxantrone. A dosage adjustment may be required for other patients with hepatic function impairment.


Functional cardiac changes, including irreversible CHF and decreased LVEF, can occur.


Ensure that hypouricemic therapy is initiated before starting treatment for leukemia and that uric acid levels are monitored frequently during treatment.


Mitoxantrone administered at any dose can cause myelosuppression. Do not administer mitoxantrone to patients with preexisting myelosuppression caused by prior drug therapy.

Patient Information

  • Explain name, dose, action, and potential adverse reactions of drug.
  • Obtain patient history, including drug history and any known allergies.
  • Advise patient to read Patient Information leaflet before starting therapy and prior to each treatment.
  • Advise patient, family, or caregiver that medication will be prepared and administered by a health care provider in a medical setting.
  • Review dose and dosing schedule, depending on condition being treated.
  • Advise patient, family, or caregiver that urine may have a blue-green color for 24 hr after administration and bluish discoloration of the sclera may occur.
  • Instruct patient to immediately report any of the following to health care provider: infusion site reaction or pain; cough or difficulty breathing on exertion; swelling of legs or feet; sores in or around the mouth; fever, sore throat, or other signs of infection; bleeding or unusual bruising.
  • Advise women of childbearing potential to use effective contraception during therapy.
  • Advise women to notify health care provider if pregnant, planning to become pregnant, or breast-feeding.
  • Instruct patient not to take any prescription or OTC medications, herbal preparations, or dietary supplements unless advised by health care provider.
  • Advise patient that follow-up visits and lab tests will be necessary to monitor therapy and to keep appointments.

Recent Drug Updates at DrugIndexOnline:

Bupropion Hydrochloride Bupropion Hydrochloride
Pronouncation: (bue-PROE-pee-on HYE-droe-KLOR-ide) Class: Antidepressant, Smoking deterrent Trade Names: Budeprion SR - Tablets, sustained-release 150 mg Trade Names: Budeprion XL - Tablets, extended-release 300 mg Trade Names: Wellbutrin - Tablets 75 mg - Tablets 100 mg Trade Names: Wellbutrin SR more...

Canasa Suppositories Canasa Suppositories
Generic Name: Mesalamine Suppositories (me-SAL-a-meen) Brand Name: CanasaCanasa Suppositories is used for:Treating various forms of mild to moderate inflammation of the colon. Canasa Suppositories is a 5-aminosalicylic acid (5-ASA). It works by preventing the production of substances that cause more...

Dextromethorphan/Potassium Guaiacolsulfonate Dextromethorphan/Potassium Guaiacolsulfonate
Generic Name: Dextromethorphan/Potassium Guaiacolsulfonate (DEX-troe-meth-OR-fan/poe-TASS-ee-um gywe-a-kole-SUL-foe-nate) Brand Name: Examples include Guiadex DM and Prolex DMDextromethorphan/Potassium Guaiacolsulfonate is used for:Temporarily relieving cough due to minor throat and airway irr more...

Evista Evista
Some commonly used brand names are: In the U.S.— Evista Category Estrogen receptor modulator, selective osteoporosis prophylactic Description Raloxifene (ral-OX-i-feen) is used to help prevent and treat thinning of the bones (osteoporosis) only in postmenopausal women. It works l more...

Ifosfamide and Mesna Ifosfamide and Mesna
Generic Name: Ifosfamide and Mesna Injection Kit (eye-FOSS-fuh-mide and MES-nuh) Brand Name: Ifex and MesnexIfosfamide and Mesna should only be used under the supervision of a doctor experienced with the use of cancer medicines. Bladder effects (eg, bleeding, inflammation) or central nervous s more...

Iressa Iressa
Generic Name: Gefitinib (geh-FIT-in-ib) Brand Name: IressaIressa is used for:Treating non-small cell lung cancer after other cancer chemotherapy treatments have not been successful. It may also be used for other conditions as determined by your doctor. Iressa is a cancer chemotherapy agent. It more...

Japanese Encephalitis Virus Vaccine Japanese Encephalitis Virus Vaccine
Some commonly used brand names are: In the U.S.— Je-Vax In Canada— Je-Vax Category Immunizing agent, active Description Japanese encephalitis (in-cef-a-LY-tis) virus vaccine is an immunizing agent used to help prevent infection by the Japanese encephalitis virus. Japanese more...

Piperacillin/Tazobactam Piperacillin/Tazobactam
Generic Name: Piperacillin/Tazobactam (PI-per-a-SIL-in/TAZ-oh-BAK-tam) Brand Name: ZosynPiperacillin/Tazobactam is used for:Treating moderate to severe infections caused by certain bacteria. Piperacillin/Tazobactam is an antibacterial agent. It works by blocking the bacteria's cell wall growth more...